Propanc Biopharma

PPCB

Market cap $3.06M

We are pleased with advancements made with our R&D programs and

As we advance toward human trials, we remain committed to delivering hope to patients facing limited options for aggressive cancers from solid tumors.

MELBOURNE, Australia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced the filing of its fourth new provisional patent application in the past two months with IP Australia. This latest application focuses on innovative formulations of the pancreatic proenzymes, trypsinogen and chymotrypsinogen— the active components in Propanc's lead asset, PRP — addressing critical challenges in stability, storage, freeze/thaw cycling, and global transport.

MELBOURNE, , Jan. 20, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that a new provisional patent application has been filed for methods of producing trypinsogen and chymotrypsinogen with IP Australia. The patent application describes an optimized expression system to produce a world-first fully synthetic recombinant version of PRP, a long-term therapy for the treatment and prevention of metastatic cancer from solid tumors.

This high unmet need has drawn interest to novel mechanisms of action — including Propanc Biopharma's pancreatic proenzyme formulation known as PRP.

MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced a shareholder update from its Chief Executive Officer and Cofounder, Mr. James Nathanielsz.

MELBOURNE, Australia, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for chronic diseases such as recurrent and metastatic cancer, today announced that the Company and its joint research partners at the Universities of Jaén and Granada published key findings in a peer reviewed journal, Scientific Reports, regarding the impact of proenzymes on pancreatic ductal adenocarcinoma (PDAC) fibroblasts. From the publishers of Nature, Scientific Reports is an online, open access journal, which publishes primary research from all areas of the natural and clinical sciences.

MELBOURNE, Australia, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for chronic diseases such as recurrent and metastatic cancer, today announced plans to investigate the phenomenon of “mesenchymal drift”—an emerging area of research that may help unlock the mechanisms behind the reversal of chronic diseases. The concept, advanced by leaders in the field including Altos Labs, Inc., aligns with Propanc's expanding research efforts into how its lead product candidate, PRP, may influence the epithelial-to-mesenchymal transition (EMT) and related pathways central not only to cancer progression but also other chronic diseases.

These patents represent a significant turning point for Propanc and commercial potential of PRP for treating chronic diseases such as cancer and fibrosis

MELBOURNE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced an update on corporate progress and reported financial results for the first quarter ended September 30, 2025 (Year end June 30). Corporate and R&D Highlights Advancing PRP Toward Phase 1b First-in-Human Trial (2026) Propanc continues to advance its lead candidate, PRP, toward a world-first Phase 1b clinical study in 30–40 patients with advanced solid tumors at the Peter Mac Cancer Center in Melbourne.